[Darolutamide: A new drug for non-metastatic castration-resistant prostate cancer].
Zhonghua Nan Ke Xue
; 26(4): 364-368, 2020 Apr.
Article
em Zh
| MEDLINE
| ID: mdl-33351306
ABSTRACT
Prostate cancer (PCa) is one of the most common tumors in male. Castration-resistant PCa (CRPC) refers to the prostate malignancy with a PSA increase or imaging progression after androgen-deprivation therapy (ADT), which is divided into metastatic CRPC (mCRPC) and non-metastatic CRPC (nmCRPC) based on the presence or absence of imaging metastasis. Two second-generation antiandrogens, enzuramide and abiraterone, were approved for the treatment of nmCRPC in 2018. A recently completed three-stage large-scale clinical ARAMIS trial shows that the new drug, darolutamide, compared with the placebo, could prolong the metastasis-free survival (MFS) of nmCRPC patients. Darolutamide is now an anti-androgen drug available for patients with nmCRPC. This review focuses on the clinical trial of darolutamide and comparison of its therapeutic effect with that of another two second-generation antiandrogens.
Palavras-chave
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Pirazóis
/
Antagonistas de Receptores de Andrógenos
/
Neoplasias de Próstata Resistentes à Castração
Tipo de estudo:
Clinical_trials
Limite:
Humans
/
Male
Idioma:
Zh
Revista:
Zhonghua Nan Ke Xue
Assunto da revista:
MEDICINA REPRODUTIVA
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
China